Sonoma Pharmaceuticals, Inc. (SNOA)
SNOA Stock Price Chart
Explore Sonoma Pharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze SNOA price movements and trends.
SNOA Company Profile
Discover essential business fundamentals and corporate details for Sonoma Pharmaceuticals, Inc. (SNOA) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
25 Jan 2007
Employees
10.00
Website
https://www.sonomapharma.comCEO
Amy Trombly
Description
Sonoma Pharmaceuticals, Inc. specializes in the creation and distribution of stabilized hypochlorous acid (HOCl) products. These offerings address a diverse range of medical and health needs, including wound management, veterinary care, ocular hygiene, oral health, and various dermatological conditions. The company's market reach extends across the United States, Latin America, Europe, and other international territories. Its comprehensive product line features: Epicyn: an antimicrobial cleanser for facial use. Levicyn: a prescription HOCl-based treatment formulated to ease the burning, itching, and pain associated with numerous dermatological issues. Celacyn gel: a topical HOCl-based prescription product engineered to facilitate efficient healing and management of both new and old scars. SebuDerm: designed to soothe the burning, itching, redness, scaling, and discomfort linked to seborrhea and seborrheic dermatitis. Acuicyn: an HOCl-based solution for alleviating ocular itch and inflammation, while also maintaining cleanliness around the eyes. Microcyn: a topical HOCl product family aimed at accelerating wound healing by combating a wide spectrum of pathogens, including antibiotic-resistant strains that can impede natural recovery. MicrocynAH: an HOCl-based solution specifically for animals, providing relief for common conditions like hot spots, scratches, skin rashes, post-surgical sites, and irritated skin to support healing. Microdacyn60: an oral care solution for treating infections of the mouth and throat. MucoClyns: suitable for emergency use and safe for application on mucous membranes, cuts, abrasions, burns, and other body surfaces. Endocyn: a series of solutions for root canal irrigation. Pediacyn: a hydrogel designed for atopic dermatitis. Ocucyn: a cleanser for eyelids and eyelashes. Gramaderm: for the topical treatment of mild to moderate acne. Nanocyn: a hospital-grade disinfectant. Sinudox: for nasal irrigation purposes. Originally incorporated in 1999 as Oculus Innovative Sciences, Inc., the company officially rebranded to Sonoma Pharmaceuticals, Inc. in December 2016. Its headquarters are located in Woodstock, Georgia.
SNOA Financial Timeline
Browse a chronological timeline of Sonoma Pharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Aug 2026
EPS estimate is -$0.30, while revenue estimate is $4.99m.
Earnings released on 16 Jun 2026
EPS came in at -$0.33 falling short of the estimated -$0.24 by -37.50%, while revenue for the quarter reached $5.56m , missing expectations by -0.08%.
Earnings released on 10 Feb 2026
EPS came in at -$0.35 falling short of the estimated -$0.29 by -20.69%, while revenue for the quarter reached $4.35m , missing expectations by -20.55%.
Earnings released on 4 Nov 2025
EPS came in at -$0.13 surpassing the estimated -$0.31 by +58.06%, while revenue for the quarter reached $5.60m , beating expectations by +31.55%.
Earnings released on 7 Aug 2025
EPS came in at -$0.37 surpassing the estimated -$0.51 by +27.45%, while revenue for the quarter reached $4.02m , missing expectations by -7.27%.
Earnings released on 17 Jun 2025
EPS came in at -$0.15 surpassing the estimated -$0.73 by +79.45%, while revenue for the quarter reached $3.75m , missing expectations by -15.44%.
Earnings released on 5 Feb 2025
EPS came in at -$0.59 surpassing the estimated -$0.80 by +26.25%, while revenue for the quarter reached $3.56m , missing expectations by -19.73%.
Earnings released on 7 Nov 2024
EPS came in at -$0.59 surpassing the estimated -$1.00 by +41.00%, while revenue for the quarter reached $3.58m , missing expectations by -18.47%.
Stock split effective on 30 Aug 2024
Shares were split 1 : 20 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 8 Aug 2024
EPS came in at -$1.40 falling short of the estimated -$0.06 by -2.23k%, while revenue for the quarter reached $3.39m , missing expectations by -10.34%.
Earnings released on 17 Jun 2024
EPS came in at -$1.40 surpassing the estimated -$3.41 by +58.92%, while revenue for the quarter reached $3.44m , missing expectations by -13.59%.
Earnings released on 8 Feb 2024
EPS came in at -$1.20 falling short of the estimated -$0.21 by -471.43%, while revenue for the quarter reached $3.14m , missing expectations by -21.16%.
Earnings released on 13 Nov 2023
EPS came in at -$4.00 falling short of the estimated -$0.24 by -1.57k%, while revenue for the quarter reached $2.73m , missing expectations by -21.52%.
Earnings released on 10 Aug 2023
EPS came in at -$5.80 falling short of the estimated -$2.40 by -141.67%, while revenue for the quarter reached $3.43m , beating expectations by +1.41%.
Earnings released on 21 Jun 2023
EPS came in at -$4.60 , while revenue for the quarter reached $3.01m , missing expectations by -8.62%.
Earnings released on 14 Feb 2023
EPS came in at -$10.00 , while revenue for the quarter reached $2.94m .
Earnings released on 14 Nov 2022
EPS came in at -$3.80 , while revenue for the quarter reached $3.33m .
Earnings released on 11 Aug 2022
EPS came in at -$5.80 , while revenue for the quarter reached $3.98m .
Earnings released on 13 Jul 2022
EPS came in at -$19.00 , while revenue for the quarter reached $2.30m .
Earnings released on 11 Feb 2022
EPS came in at -$6.20 , while revenue for the quarter reached $2.90m .
Earnings released on 15 Nov 2021
EPS came in at -$0.80 , while revenue for the quarter reached $3.74m .
Earnings released on 16 Aug 2021
EPS came in at -$10.40 , while revenue for the quarter reached $3.68m .
SNOA Stock Performance
Access detailed SNOA performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
